Skip to main content

Table 6 Summary of participants with single or multiple injection-site reactions excluding pain among pooled galcanezumab-treated participants in Study CGAJ and REGAIN (galcanezumab exposure analysis set)

From: Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine

Injection-site reactions, n (%)
Total doses received (N = 1326)1 to 34 to 9> 10
 1 (26)2 (7.7)00
 2 (36)2 (5.6)00
 3 (32)1 (3.1)1 (3.1)0
 4 (35)6 (17.1)00
 5 (32)6 (18.8)00
 6 (39)5 (12.8)3 (7.7)0
 7 (29)7 (24.1)2 (6.9)0
 8 (26)7 (26.9)00
 9a (433)30 (6.9)12 (2.8)2 (0.5)
 10 (9)3 (33.3)1 (11.1)0
 11 (11)2 (18.2)00
 12 (618)97 (15.7)34 (5.5)6 (1.0)
  1. athe number of patients receiving up to nine doses of galcanezumab, includes patients from both Study CGAJ (Month 0 to Month 12) and REGAIN (galcanezumab, Month 0 to Month 12; and placebo patients who had received placebo treatment from Month 0 to Month 3 and then initiated galcanezumab in the open-label extension phase and could receive up to nine doses of galcanezumab
  2. Abbreviations:N number of galcanezumab-treated participants with a specific number of galcanezumab doses, n number of patients within each specific category